1.20.10
Madeira Therapeutics to Speak at the Annual Drug Delivery Partnerships Meeting
(LEAWOOD, KS; January 20, 2010) – Madeira Therapeutics, a Kansas-based company specializing in pediatric pharmaceuticals, announced today that Peter Joiner, Madeira president and chief executive officer, will address the pediatric segment of the “Drug Delivery and Development for Specialized Populations: Pediatric and Geriatric Products” workshop at the 14th Annual Drug Delivery Partnerships Meeting held January 25-27, 2010, in Orlando, FL.
Joiner was invited to share his knowledge and expertise on the topic of pediatric drug development and delivery. His presentation will take place on Monday, January 25, from 1 p.m. to 4 p.m. at the Omni Champion’s Gate Resort.
As Joiner explores different strategies of reformulating and repositioning adult formulations, his presentation will also deliver a thorough discussion of the following topics: overcoming challenges with minimal pediatric resources by contrast of the adult side, overcoming pediatric formulation issues and limitations in developing liquid and oral products, and reviewing the pediatric marketplace to determine what the specific needs are and the best way to meet them.
“I am truly honored to have the opportunity to speak on this topic. It is very much an important issue for today and should be addressed. As we continue to develop our first drug, MT-001—the first ever liquid preparation of a cholesterol-lowering statin for children and the elderly, I am happy to share my findings and research with this audience,” said Joiner.
About Madeira Therapeutics
Madeira Therapeutics, LLC, is a privately held, specialty pharmaceutical company focused on providing safe and effective medicine to pediatric and geriatric patients, parents, and the healthcare professionals who serve them. The Madeira strategy focuses on reformulating adult drugs for better dosage control in children. Madeira utilizes the FDA’s 505(b)(2) approval method, which relies in part on the regulatory agency’s findings for a drug previously approved for adults, thereby shortcutting IND approval by years and saving tens of millions of dollars in development costs. The company’s lead program, MT-001, is the first ever liquid preparation of a statin developed for the geriatric and pediatric population. The company’s second product is MT-003 for acute pain relief. For more information, please visit http://www.madeiratherapeutics.com/.
